Free Trial
→ July 2025 Rule Change to Impact Retirement Investors (From Premier Gold Co) (Ad) Buy SUPN Stock  Free SUPN Stock Alerts

Supernus Pharmaceuticals (SUPN) Financials

Supernus Pharmaceuticals logo
$32.15 -0.45 (-1.38%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$32.15 0.00 (0.00%)
As of 05/28/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Supernus Pharmaceuticals

Annual Income Statements for Supernus Pharmaceuticals

This table shows Supernus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 74 1.32 61 53 127 113 111 57 511 14 -11
Consolidated Net Income / (Loss)		 74 1.32 61 53 127 113 111 57 91 14 -11
Net Income / (Loss) Continuing Operations		 74 1.32 61 53 127 113 111 57 511 14 -11
Total Pre-Tax Income 		98 2.77 61 73 169 147 140 101 50 15 -10
Total Operating Income		 82 -5.27 46 86 174 149 144 100 54 21 -5.28
Total Gross Profit		 584 524 580 505 468 376 394 287 413 139 87
Total Revenue		 662 608 667 580 520 393 409 302 425 147 93
Operating Revenue		 662 608 667 580 520 393 409 302 425 147 93
Total Cost of Revenue		 78 84 87 75 52 17 15 15 12 8.42 5.76
Operating Cost of Revenue		 78 84 87 75 52 17 15 15 12 8.42 5.76
Total Operating Expenses		 502 529 534 419 294 228 249 187 -61 118 92
Selling, General & Admin Expense		 322 336 377 305 201 153 155 138 106 89 73
Research & Development Expense		 109 92 75 90 76 69 89 50 43 29 20
Amortization Expense		 78 82 83 30 16 5.18 5.19 - - - -
Impairment Charge		 0.00 20 0.00 - - - - - - - -
Other Special Charges / (Income)		 -6.11 -1.52 -0.51 -6.53 1.90 0.00 0.00 - - - -
Total Other Income / (Expense), net		 16 8.04 15 -13 -5.05 -1.08 -4.27 1.08 -3.85 -6.23 -5.02
Interest Expense		 0.00 2.42 7.07 - - - - - 5.76 7.11 8.21
Other Income / (Expense), net		 16 10 22 -13 -5.05 -1.08 -4.27 1.08 0.45 0.19 2.85
Income Tax Expense		 24 1.45 0.03 20 42 34 29 43 -41 0.67 0.63
Basic Earnings per Share		 $1.34 $0.02 $1.13 $1.01 $2.41 $2.16 $2.13 $1.13 $1.84 $0.29 ($0.26)
Weighted Average Basic Shares Outstanding		 55.10M 54.54M 53.67M 53.10M 52.62M 52.41M 51.99M 50.76M 49.47M 47.49M 42.26M
Diluted Earnings per Share		 $1.32 $0.02 $1.04 $0.98 $2.36 $2.10 $2.05 $1.08 $1.76 $0.28 ($0.26)
Weighted Average Diluted Shares Outstanding		 55.96M 55.51M 61.68M 54.36M 53.69M 53.82M 54.10M 53.30M 51.71M 51.16M 42.26M
Weighted Average Basic & Diluted Shares Outstanding		 55.81M - 54.38M 53.39M 52.92M 52.53M 52.32M 51.54M 49.60M 48.10M 42.30M

Quarterly Income Statements for Supernus Pharmaceuticals

This table shows Supernus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -12 15 38 20 0.12 1.18 -16 -0.83 17 25 1.75
Consolidated Net Income / (Loss)		 -12 15 38 20 0.12 1.18 -16 -0.83 17 25 1.75
Net Income / (Loss) Continuing Operations		 -12 15 38 20 0.12 1.18 -16 -0.83 17 25 1.75
Total Pre-Tax Income 		-5.83 26 45 26 0.24 0.99 9.89 -17 9.02 35 -0.44
Total Operating Income		 -10 21 41 23 -3.15 -1.00 8.14 -18 5.18 34 -1.52
Total Gross Profit		 134 148 158 150 127 145 134 114 130 144 151
Total Revenue		 150 174 176 168 144 164 154 136 154 167 177
Operating Revenue		 150 174 176 168 144 164 154 136 154 167 177
Total Cost of Revenue		 16 26 18 18 16 20 20 21 23 23 26
Operating Cost of Revenue		 16 26 18 18 16 20 20 21 23 23 26
Total Operating Expenses		 144 127 117 128 130 146 126 132 125 110 153
Selling, General & Admin Expense		 90 79 70 86 87 81 83 87 86 74 112
Research & Development Expense		 27 29 29 26 25 23 23 24 21 18 20
Amortization Expense		 20 18 19 20 20 21 21 20 20 21 21
Other Special Charges / (Income)		 7.66 0.36 -1.02 -4.36 -1.10 -0.20 -0.46 0.79 -1.65 -2.40 0.49
Total Other Income / (Expense), net		 4.43 4.98 4.10 3.73 3.40 1.99 1.75 0.46 3.84 0.81 1.08
Other Income / (Expense), net		 4.43 4.98 4.10 3.73 3.40 1.99 1.75 1.37 5.35 2.40 2.80
Income Tax Expense		 6.00 11 6.45 6.39 0.12 -0.19 26 -16 -7.93 9.66 -2.19
Basic Earnings per Share		 ($0.21) $0.28 $0.70 $0.36 $0.00 $0.02 ($0.29) ($0.02) $0.31 $0.47 $0.03
Weighted Average Basic Shares Outstanding		 55.86M 55.10M 55.15M 54.98M 54.80M 54.54M 54.61M 54.50M 54.38M 53.67M 53.79M
Diluted Earnings per Share		 ($0.21) $0.27 $0.69 $0.36 $0.00 $0.04 ($0.29) ($0.02) $0.29 $0.44 $0.03
Weighted Average Diluted Shares Outstanding		 55.86M 55.96M 56.02M 55.72M 55.63M 55.51M 54.61M 54.50M 62.45M 61.68M 55.03M
Weighted Average Basic & Diluted Shares Outstanding		 55.99M 55.81M 55.22M 55.11M 54.97M 0.00 54.63M 54.59M 54.48M 54.38M 54.06M

Annual Cash Flow Statements for Supernus Pharmaceuticals

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -5.72 -18 -110 -85 107 -11 92 34 -58 -2.90 3.42
Net Cash From Operating Activities		 172 111 117 127 138 143 129 115 67 35 -24
Net Cash From Continuing Operating Activities		 172 111 117 127 138 143 129 115 -24 35 -24
Net Income / (Loss) Continuing Operations		 74 1.32 61 53 127 113 111 57 0.00 14 -11
Consolidated Net Income / (Loss)		 74 1.32 61 53 127 113 111 57 - 14 -11
Depreciation Expense		 80 85 86 33 18 6.66 7.06 8.13 2.40 0.92 0.93
Amortization Expense		 1.82 0.41 5.35 18 14 12 10 -0.51 0.52 0.75 2.09
Non-Cash Adjustments To Reconcile Net Income		 59 61 16 31 14 17 48 31 22 25 13
Changes in Operating Assets and Liabilities, net		 -43 -36 -51 -7.95 -34 -5.03 -48 18 -49 -6.35 -29
Net Cash From Investing Activities		 -190 269 -217 -82 -35 -158 -413 -86 -36 -39 -2.66
Net Cash From Continuing Investing Activities		 -190 269 -217 -82 -35 -158 -413 -86 -36 -39 -2.66
Purchase of Property, Plant & Equipment		 -0.73 -0.55 -0.41 -2.05 -3.69 -1.39 -0.84 -2.03 -1.60 -2.10 -0.59
Purchase of Investments		 -688 -102 -407 -312 -96 -410 -492 -102 -47 -64 -53
Sale and/or Maturity of Investments		 499 371 191 531 378 253 80 29 32 38 53
Net Cash From Financing Activities		 12 -398 -10 -130 3.56 3.93 376 5.68 2.05 1.87 31
Net Cash From Continuing Financing Activities		 12 -398 -10 -130 3.56 3.93 376 5.68 2.05 1.87 31
Repayment of Debt		 0.00 -496 0.00 -138 0.00 0.00 - - - - -
Issuance of Debt		 0.00 93 0.00 - - - 403 0.00 - - 0.00
Issuance of Common Equity		 15 6.61 12 7.10 4.36 3.93 77 5.68 2.05 1.87 0.57
Other Financing Activities, net		 -2.72 -1.99 -23 0.80 -0.80 0.00 -93 0.00 - - 30
Cash Interest Paid		 0.00 1.95 2.52 2.52 2.52 2.52 1.34 0.13 0.49 0.83 2.85
Cash Income Taxes Paid		 53 37 16 25 45 52 35 1.59 - - -

Quarterly Cash Flow Statements for Supernus Pharmaceuticals

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 47 38 -20 -11 -12 -20 70 -437 369 -18 -62
Net Cash From Operating Activities		 31 44 54 36 38 45 36 -19 49 28 14
Net Cash From Continuing Operating Activities		 31 44 54 36 38 45 36 -19 49 28 14
Net Income / (Loss) Continuing Operations		 -12 15 38 20 0.12 1.18 -16 -0.83 17 25 1.75
Consolidated Net Income / (Loss)		 -12 15 38 20 0.12 1.18 -16 -0.83 17 25 1.75
Depreciation Expense		 20 19 20 21 21 22 22 21 21 21 22
Amortization Expense		 -1.07 -0.67 0.97 -0.36 1.89 0.73 0.07 0.14 -0.52 0.55 2.68
Non-Cash Adjustments To Reconcile Net Income		 10 15 24 11 8.35 30 9.98 12 8.77 7.92 3.22
Changes in Operating Assets and Liabilities, net		 13 -4.43 -30 -15 7.29 -8.69 20 -51 3.34 -27 -16
Net Cash From Investing Activities		 37 -13 -77 -49 -52 -66 35 60 240 -49 -82
Net Cash From Continuing Investing Activities		 37 -13 -77 -49 -52 -66 35 60 240 -49 -82
Purchase of Property, Plant & Equipment		 -0.33 -0.21 -0.20 -0.06 -0.25 0.04 -0.15 -0.16 -0.28 0.01 -0.15
Purchase of Investments		 -119 -145 -225 -124 -194 -102 - - 0.00 -66 -134
Sale and/or Maturity of Investments		 156 133 148 75 142 36 35 60 240 18 52
Net Cash From Financing Activities		 -21 5.89 3.08 1.66 1.57 1.09 -0.23 -479 80 2.83 6.46
Net Cash From Continuing Financing Activities		 -21 5.89 3.08 1.66 1.57 1.09 -0.23 -479 80 2.83 6.46
Issuance of Common Equity		 2.04 6.88 3.46 1.66 2.91 1.09 0.74 2.52 2.26 2.83 6.46
Other Financing Activities, net		 -23 -0.99 -0.39 -0.00 -1.34 - -0.97 -0.58 -0.45 - -
Cash Income Taxes Paid		 0.27 13 20 20 0.34 9.55 6.62 20 0.20 1.64 6.02

Annual Balance Sheets for Supernus Pharmaceuticals

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 1,368 1,278 1,703 1,689 1,504 1,160 978 424 310 189 137
Total Current Assets		 686 493 734 602 630 473 493 228 151 106 109
Cash & Equivalents		 69 75 93 203 289 181 192 100 66 33 36
Short-Term Investments		 384 180 368 136 134 166 164 40 24 29 38
Accounts Receivable		 142 144 165 149 141 87 103 66 42 26 17
Inventories, net		 54 77 92 86 48 27 26 16 17 13 13
Prepaid Expenses		 36 17 16 27 19 12 8.89 6.52 2.96 5.26 3.68
Plant, Property, & Equipment, net		 12 14 15 0.00 0.00 17 4.10 5.12 4.34 3.87 2.45
Total Noncurrent Assets		 670 771 953 1,088 874 671 480 191 154 79 26
Long-Term Investments		 0.00 17 94 119 350 592 419 134 75 55 20
Goodwill		 117 117 117 118 78 0.00 - - - - -
Intangible Assets		 522 600 702 785 364 25 31 36 36 0.98 0.23
Other Noncurrent Operating Assets		 32 38 40 66 81 22 0.38 0.39 0.33 23 5.57
Total Liabilities & Shareholders' Equity		 1,368 1,278 1,703 1,689 1,504 1,160 978 424 310 189 137
Total Liabilities		 332 356 816 873 759 565 525 157 118 101 96
Total Current Liabilities		 292 290 688 315 245 161 161 123 81 57 28
Short-Term Debt		 47 52 423 45 31 0.00 - - - - -
Accounts Payable		 76 80 96 118 79 50 40 6.84 8.06 4.31 1.86
Accrued Expenses		 169 154 152 133 126 108 107 96 69 52 26
Other Current Liabilities		 0.00 4.28 17 20 9.08 3.24 2.18 4.28 3.10 0.50 -
Total Noncurrent Liabilities		 40 66 128 558 514 404 363 34 37 44 68
Noncurrent Deferred & Payable Income Tax Liabilities		 4.96 25 50 85 35 0.00 - - - - -
Other Noncurrent Operating Liabilities		 35 41 79 52 89 59 34 33 31 35 40
Commitments & Contingencies		 0.00 0.00 - - - - - - - - -
Total Equity & Noncontrolling Interests		 1,036 922 886 816 745 595 453 267 192 88 41
Total Preferred & Common Equity		 1,036 922 886 816 745 595 453 267 192 88 41
Total Common Equity		 1,036 922 886 816 745 595 453 267 192 88 41
Common Stock		 479 440 408 434 409 388 370 295 276 264 230
Retained Earnings		 556 483 481 380 326 200 86 -27 -84 -176 -189
Accumulated Other Comprehensive Income / (Loss)		 -0.19 -0.59 -3.21 1.54 8.98 7.42 -3.16 -0.75 -0.13 -0.49 -0.15

Quarterly Balance Sheets for Supernus Pharmaceuticals

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,347 1,343 1,316 1,304 1,285 1,293 1,792 1,693
Total Current Assets		 688 640 591 544 449 424 883 664
Cash & Equivalents		 116 32 52 63 95 25 58 111
Short-Term Investments		 348 372 295 234 105 127 170 280
Accounts Receivable		 146 145 152 148 142 137 144 164
Inventories, net		 49 64 68 75 83 91 91 83
Prepaid Expenses		 29 27 23 24 24 45 16 25
Plant, Property, & Equipment, net		 11 12 12 13 14 14 15 0.00
Total Noncurrent Assets		 648 691 713 747 822 855 894 1,029
Goodwill		 117 117 117 117 117 117 117 117
Intangible Assets		 502 540 560 580 641 662 682 723
Other Noncurrent Operating Assets		 29 34 36 38 39 38 40 57
Total Liabilities & Shareholders' Equity		 1,347 1,343 1,316 1,304 1,285 1,293 1,792 1,693
Total Liabilities		 317 336 358 375 373 373 880 840
Total Current Liabilities		 282 292 309 315 288 253 732 726
Short-Term Debt		 30 47 47 51 46 21 481 449
Accounts Payable		 77 76 83 86 78 83 95 110
Accrued Expenses		 170 169 175 167 162 149 148 158
Other Current Liabilities		 4.75 0.00 3.62 9.55 0.71 0.00 7.49 8.19
Total Noncurrent Liabilities		 35 44 50 60 85 121 148 114
Noncurrent Deferred & Payable Income Tax Liabilities		 0.98 7.36 11 20 35 44 50 58
Other Noncurrent Operating Liabilities		 34 37 38 41 50 76 98 56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - - - -
Total Equity & Noncontrolling Interests		 1,031 1,007 957 929 912 920 912 853
Total Preferred & Common Equity		 1,031 1,007 957 929 912 920 912 853
Total Common Equity		 1,031 1,007 957 929 912 920 912 853
Common Stock		 486 466 455 447 432 424 416 401
Retained Earnings		 545 541 503 483 481 497 498 456
Accumulated Other Comprehensive Income / (Loss)		 -0.16 0.08 -0.37 -0.53 -1.21 -1.78 -2.33 -4.05

Annual Metrics And Ratios for Supernus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 8.94% -8.95% 15.09% 11.41% 32.50% -3.95% 35.29% -28.90% 188.26% 59.12% 671.10%
EBITDA Growth		 99.12% -43.00% 28.31% -38.30% 20.90% 5.33% 45.44% 87.97% 153.60% 3,761.56% 100.82%
EBIT Growth		 1,787.92% -92.36% -7.33% -56.61% 14.35% 5.22% 39.32% 84.07% 159.85% 965.72% 96.77%
NOPAT Growth		 2,561.33% -105.43% -26.60% -51.96% 14.81% -0.42% 101.82% -42.28% 393.56% 638.46% 91.48%
Net Income Growth		 5,512.84% -97.83% 13.64% -57.92% 12.29% 1.86% 93.76% -37.20% 554.20% 227.63% 88.16%
EPS Growth		 6,500.00% -98.08% 6.12% -58.47% 12.38% 2.44% 89.81% -38.64% 528.57% 207.69% 91.03%
Operating Cash Flow Growth		 54.79% -4.91% -8.10% -8.14% -3.30% 10.96% 12.51% 71.59% 93.52% 240.94% 57.73%
Free Cash Flow Firm Growth		 171.46% -56.78% 131.23% -40.55% -317.60% 19.20% 7.77% 104.10% 209.34% 3,216.30% 101.57%
Invested Capital Growth		 -10.35% -6.89% -8.31% 109.16% 22,342.69% -77.15% 223.73% -120.40% 237.46% 18.81% -17.93%
Revenue Q/Q Growth		 0.00% -0.49% 1.26% 2.75% 8.49% -4.59% 8.86% -37.84% 116.53% 9.22% 29.12%
EBITDA Q/Q Growth		 0.00% -23.42% 53.24% -19.05% -6.21% 0.59% 3.58% 22.13% 18.55% 8.49% 101.67%
EBIT Q/Q Growth		 0.00% -84.69% 333.56% -33.87% -9.97% 1.34% 0.89% 23.47% 18.20% 11.22% 93.72%
NOPAT Q/Q Growth		 0.00% -112.00% 89.18% -30.74% 0.14% 5.97% 13.76% -2.66% 7.20% 9.99% 75.74%
Net Income Q/Q Growth		 0.00% -94.86% 61.16% -34.65% -1.83% 6.84% 12.39% -1.14% 8.91% 28.19% 41.59%
EPS Q/Q Growth		 0.00% -95.24% 62.50% -35.10% -1.67% 7.14% 10.22% -3.57% 11.39% 16.67% 83.65%
Operating Cash Flow Q/Q Growth		 0.00% 18.57% -15.36% 15.26% -7.89% 8.28% -2.63% 11.04% 8.11% 65.50% 39.04%
Free Cash Flow Firm Q/Q Growth		 63.27% -25.29% 129.03% -329.50% 10.91% 9.65% -6.47% 22.71% 2.27% 122.85% 102.17%
Invested Capital Q/Q Growth		 -3.24% -4.18% -3.09% 128.76% -8.23% -66.82% 8.43% -144.30% -4.35% -45.99% -2.36%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.23% 86.21% 86.93% 87.05% 89.92% 95.76% 96.24% 94.97% 97.18% 94.29% 93.79%
EBITDA Margin		 27.21% 14.89% 23.78% 21.33% 38.52% 42.22% 38.50% 35.81% 13.55% 15.40% 0.63%
Operating Margin		 12.34% -0.87% 6.91% 14.84% 33.38% 37.83% 35.33% 32.93% 12.75% 14.13% -5.70%
EBIT Margin		 14.79% 0.85% 10.16% 12.62% 32.41% 37.55% 34.28% 33.29% 12.86% 14.27% -2.62%
Profit (Net Income) Margin		 11.16% 0.22% 9.10% 9.21% 24.39% 28.79% 27.14% 18.95% 21.46% 9.46% -11.79%
Tax Burden Percent		 75.47% 47.53% 99.95% 73.01% 75.28% 76.65% 79.18% 56.93% 181.11% 95.44% 106.12%
Interest Burden Percent		 100.00% 53.41% 89.57% 100.00% 100.00% 100.00% 100.00% 100.00% 92.14% 69.45% 423.66%
Effective Tax Rate		 24.53% 52.47% 0.05% 26.99% 24.72% 23.35% 20.82% 43.07% -81.11% 4.56% 0.00%
Return on Invested Capital (ROIC)		 9.26% -0.34% 5.85% 10.33% 66.21% 2,417.73% 15,550.30% 468.53% 2,371.12% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 5.35% -2.52% -17.42% 15.77% 67.02% 2,417.89% 15,551.24% 468.25% 2,376.25% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -1.71% 0.49% 1.29% -3.49% -47.27% -2,396.16% -15,519.49% -443.58% -2,305.91% 0.00% 0.00%
Return on Equity (ROE)		 7.55% 0.15% 7.13% 6.85% 18.94% 21.57% 30.81% 24.95% 65.21% 21.67% -29.46%
Cash Return on Invested Capital (CROIC)		 20.17% 6.79% 14.52% -60.28% -132.01% 2,543.34% 1,310.54% 0.00% 150.36% 0.00% 0.00%
Operating Return on Assets (OROA)		 7.40% 0.35% 4.00% 4.58% 12.66% 13.80% 19.99% 27.42% 21.94% 12.93% -1.96%
Return on Assets (ROA)		 5.58% 0.09% 3.58% 3.35% 9.53% 10.58% 15.83% 15.61% 36.62% 8.57% -8.82%
Return on Common Equity (ROCE)		 7.55% 0.15% 7.13% 6.85% 18.94% 21.57% 30.81% 24.95% 65.21% 21.67% -29.46%
Return on Equity Simple (ROE_SIMPLE)		 7.13% 0.14% 6.85% 6.55% 17.04% 18.99% 24.50% 21.42% 47.57% 15.84% -26.84%
Net Operating Profit after Tax (NOPAT)		 62 -2.50 46 63 131 114 114 57 98 20 -3.69
NOPAT Margin		 9.31% -0.41% 6.91% 10.83% 25.13% 29.00% 27.97% 18.75% 23.10% 13.49% -3.99%
Net Nonoperating Expense Percent (NNEP)		 3.91% 2.17% 23.27% -5.44% -0.80% -0.16% -0.94% 0.28% -5.13% -6.68% -11.62%
Return On Investment Capital (ROIC_SIMPLE)		 5.69% -0.26% 3.52% - - - - - - - -
Cost of Revenue to Revenue		 11.77% 13.79% 13.07% 12.95% 10.08% 4.24% 3.76% 5.03% 2.82% 5.71% 6.21%
SG&A Expenses to Revenue		 48.59% 55.37% 56.53% 52.57% 38.56% 39.02% 37.83% 45.63% 24.94% 60.40% 78.35%
R&D to Revenue		 16.44% 15.08% 11.17% 15.60% 14.60% 17.59% 21.82% 16.40% 10.07% 19.76% 21.13%
Operating Expenses to Revenue		 75.89% 87.08% 80.02% 72.22% 56.54% 57.93% 60.92% 62.03% -14.42% 80.15% 99.48%
Earnings before Interest and Taxes (EBIT)		 98 5.18 68 73 169 147 140 101 55 21 -2.43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 180 90 159 124 200 166 157 108 58 23 0.59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.93 1.72 2.18 1.90 1.78 2.09 3.83 7.64 6.52 7.47 8.76
Price to Tangible Book Value (P/TBV)		 5.03 7.73 28.90 0.00 4.38 2.18 4.12 8.83 8.04 7.56 8.80
Price to Revenue (P/Rev)		 3.02 2.60 2.89 2.67 2.55 3.17 4.25 6.76 2.94 4.46 3.84
Price to Earnings (P/E)		 27.03 1,201.42 31.76 29.03 10.44 11.01 15.64 35.66 2.44 47.16 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.70% 0.08% 3.15% 3.45% 9.58% 9.09% 6.39% 2.80% 40.91% 2.12% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.53 1.94 2.38 1.89 2.48 371.43 168.29 0.00 35.83 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.40 2.24 2.69 2.69 1.87 1.66 3.16 5.85 2.56 3.71 3.11
Enterprise Value to EBITDA (EV/EBITDA)		 8.83 15.05 11.32 12.59 4.86 3.92 8.20 16.34 18.91 24.11 490.46
Enterprise Value to EBIT (EV/EBIT)		 16.25 262.66 26.49 21.28 5.77 4.41 9.21 17.58 19.92 26.02 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 25.80 0.00 38.96 24.79 7.45 5.71 11.28 31.22 11.09 27.52 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 9.25 12.26 15.37 12.25 7.04 4.55 10.01 15.43 16.30 15.86 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.85 27.53 15.70 0.00 0.00 5.43 12.84 18.97 23.83 37.06 647.49
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.05 0.06 0.48 0.57 0.57 0.58 0.73 0.00 0.02 0.08 0.64
Long-Term Debt to Equity		 0.00 0.00 0.00 0.52 0.52 0.58 0.73 0.00 0.02 0.08 0.64
Financial Leverage		 -0.32 -0.19 -0.07 -0.22 -0.71 -0.99 -1.00 -0.95 -0.97 -1.38 -1.68
Leverage Ratio		 1.35 1.65 1.99 2.05 1.99 2.04 1.95 1.60 1.78 2.53 3.34
Compound Leverage Factor		 1.35 0.88 1.78 2.05 1.99 2.04 1.95 1.60 1.64 1.76 14.15
Debt to Total Capital		 4.37% 5.35% 32.31% 36.32% 36.12% 36.70% 42.10% 0.00% 2.13% 7.45% 39.18%
Short-Term Debt to Total Capital		 4.37% 5.35% 32.31% 3.50% 2.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 32.82% 33.47% 36.70% 42.10% 0.00% 2.13% 7.45% 39.18%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.63% 94.65% 67.69% 63.68% 63.88% 63.30% 57.90% 100.00% 97.87% 92.55% 60.82%
Debt to EBITDA		 0.26 0.58 2.67 3.76 2.10 2.08 2.09 0.00 0.07 0.31 44.60
Net Debt to EBITDA		 -2.26 -2.43 -0.83 0.05 -1.75 -3.58 -2.83 0.00 -2.80 -4.85 -115.53
Long-Term Debt to EBITDA		 0.00 0.00 0.00 3.40 1.95 2.08 2.09 0.00 0.07 0.31 44.60
Debt to NOPAT		 0.77 -20.79 9.18 7.41 3.22 3.03 2.88 0.00 0.04 0.36 -7.10
Net Debt to NOPAT		 -6.59 87.62 -2.87 0.10 -2.69 -5.21 -3.89 0.00 -1.64 -5.54 18.39
Long-Term Debt to NOPAT		 0.00 0.00 0.00 6.70 2.99 3.03 2.88 0.00 0.04 0.36 -7.10
Altman Z-Score		 5.24 3.87 2.37 2.07 2.37 2.64 3.41 9.51 8.22 4.08 1.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.35 1.70 1.07 1.91 2.57 2.94 3.06 1.86 1.88 1.86 3.87
Quick Ratio		 2.04 1.38 0.91 1.55 2.30 2.71 2.84 1.67 1.63 1.55 3.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 134 49 114 -366 -261 120 101 93 46 15 0.45
Operating Cash Flow to CapEx		 23,717.38% 20,160.62% 28,355.83% 6,216.48% 3,750.65% 10,319.32% 15,282.70% 5,650.07% 4,167.94% 1,640.87% -4,130.69%
Free Cash Flow to Firm to Interest Expense		 0.00 20.48 16.19 0.00 0.00 0.00 0.00 0.00 7.93 2.08 0.05
Operating Cash Flow to Interest Expense		 0.00 46.00 16.52 0.00 0.00 0.00 0.00 0.00 11.60 4.86 -2.98
Operating Cash Flow Less CapEx to Interest Expense		 0.00 45.77 16.47 0.00 0.00 0.00 0.00 0.00 11.32 4.56 -3.05
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.50 0.41 0.39 0.36 0.39 0.37 0.58 0.82 1.71 0.91 0.75
Accounts Receivable Turnover		 4.62 3.92 4.24 4.00 4.56 4.13 4.85 5.64 12.61 6.83 8.30
Inventory Turnover		 1.18 0.99 0.98 1.12 1.40 0.64 0.73 0.92 0.82 0.65 0.56
Fixed Asset Turnover		 52.79 42.33 0.00 0.00 0.00 37.12 88.71 63.84 103.45 46.65 37.06
Accounts Payable Turnover		 1.00 0.95 0.82 0.76 0.82 0.37 0.66 2.04 1.94 2.73 2.30
Days Sales Outstanding (DSO)		 78.93 93.02 86.00 91.23 80.03 88.40 75.21 64.68 28.95 53.44 43.96
Days Inventory Outstanding (DIO)		 308.52 368.03 371.40 326.49 260.75 572.77 498.71 397.09 447.46 563.95 652.70
Days Payable Outstanding (DPO)		 365.26 383.20 447.82 478.05 447.55 979.80 553.51 178.71 188.33 133.84 158.63
Cash Conversion Cycle (CCC)		 22.19 77.85 9.58 -60.33 -106.77 -318.63 20.41 283.05 288.08 483.55 538.02
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 629 702 754 822 393 1.75 7.67 -6.20 30 -22 -27
Invested Capital Turnover		 0.99 0.83 0.85 0.95 2.64 83.38 555.94 24.99 102.65 -5.98 -3.68
Increase / (Decrease) in Invested Capital		 -73 -52 -68 429 391 -5.92 14 -37 52 5.12 -4.14
Enterprise Value (EV)		 1,590 1,362 1,796 1,557 974 651 1,291 1,769 1,089 547 288
Market Capitalization		 1,997 1,581 1,928 1,551 1,326 1,244 1,736 2,043 1,250 658 356
Book Value per Share		 $18.76 $16.87 $16.39 $15.34 $14.14 $11.35 $8.67 $5.22 $3.87 $1.80 $0.95
Tangible Book Value per Share		 $7.19 $3.75 $1.23 ($1.62) $5.74 $10.88 $8.07 $4.52 $3.14 $1.78 $0.94
Total Capital		 1,083 974 1,309 1,281 1,166 941 782 267 196 95 67
Total Debt		 47 52 423 465 421 345 329 0.00 4.17 7.09 26
Total Long-Term Debt		 0.00 0.00 0.00 421 390 345 329 0.00 4.17 7.09 26
Net Debt		 -406 -219 -132 6.54 -352 -594 -445 -274 -161 -110 -68
Capital Expenditures (CapEx)		 0.73 0.55 0.41 2.05 3.69 1.39 0.84 2.03 1.60 2.10 0.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 0.11 7.95 -8.63 -6.32 -35 -24 -35 -19 -13 6.27
Debt-free Net Working Capital (DFNWC)		 441 255 469 331 416 312 332 105 71 49 81
Net Working Capital (NWC)		 394 203 46 286 385 312 332 105 71 49 81
Net Nonoperating Expense (NNE)		 -12 -3.82 -15 9.38 3.80 0.83 3.38 -0.61 6.97 5.95 7.23
Net Nonoperating Obligations (NNO)		 -406 -219 -132 6.54 -352 -594 -445 -274 -161 -110 -68
Total Depreciation and Amortization (D&A)		 82 85 91 51 32 18 17 7.62 2.92 1.67 3.02
Debt-free, Cash-free Net Working Capital to Revenue		 -1.90% 0.02% 1.19% -1.49% -1.22% -8.92% -5.84% -11.44% -4.58% -8.94% 6.76%
Debt-free Net Working Capital to Revenue		 66.64% 41.97% 70.33% 57.10% 79.98% 79.45% 81.23% 34.89% 16.62% 33.24% 86.97%
Net Working Capital to Revenue		 59.48% 33.40% 6.92% 49.37% 74.04% 79.45% 81.23% 34.89% 16.62% 33.24% 86.97%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.34 $0.00 $1.13 $1.01 $2.41 $2.16 $2.13 $1.13 $1.84 $0.30 $0.47
Adjusted Weighted Average Basic Shares Outstanding		 55.10M 0.00 53.67M 53.10M 52.62M 52.41M 51.99M 50.76M 49.47M 47.49M 42.26M
Adjusted Diluted Earnings per Share		 $1.32 $0.00 $1.04 $0.98 $2.36 $2.10 $2.05 $1.08 $1.76 $0.28 $0.32
Adjusted Weighted Average Diluted Shares Outstanding		 55.96M 0.00 61.68M 54.36M 53.69M 53.82M 54.10M 53.30M 51.71M 51.16M 50.58M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $2.16 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 55.81M 0.00 54.38M 53.39M 52.92M 52.53M 52.32M 51.54M 50.16M 49.40M 44.09M
Normalized Net Operating Profit after Tax (NOPAT)		 57 9.38 46 58 132 114 114 57 38 20 -3.69
Normalized NOPAT Margin		 8.62% 1.54% 6.83% 10.01% 25.40% 29.00% 27.97% 18.75% 8.93% 13.49% -3.99%
Pre Tax Income Margin		 14.79% 0.46% 9.10% 12.62% 32.41% 37.55% 34.28% 33.29% 11.85% 9.91% -11.11%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 2.15 9.59 0.00 0.00 0.00 0.00 0.00 9.49 2.96 -0.30
NOPAT to Interest Expense		 0.00 -1.04 6.52 0.00 0.00 0.00 0.00 0.00 17.04 2.80 -0.45
EBIT Less CapEx to Interest Expense		 0.00 1.92 9.53 0.00 0.00 0.00 0.00 0.00 9.21 2.66 -0.37
NOPAT Less CapEx to Interest Expense		 0.00 -1.27 6.46 0.00 0.00 0.00 0.00 0.00 16.76 2.50 -0.52
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.40% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Supernus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 4.30% 5.99% 14.17% 24.17% -6.58% -1.80% -13.24% -20.28% 0.82% 5.20% 19.46%
EBITDA Growth		 -41.11% 90.45% 107.49% 904.02% -25.21% -59.76% 23.64% -87.32% -19.88% 1,840.29% -45.82%
EBIT Growth		 -2,499.59% 2,564.85% 354.47% 262.19% -97.69% -97.30% 672.58% -223.47% -36.86% 337.95% -96.33%
NOPAT Growth		 -346.21% 1,152.04% 366.12% 238.81% -116.54% -104.75% -1,133.21% -256.22% 184.27% 242.90% -104.39%
Net Income Growth		 -9,637.90% 1,204.51% 340.97% 2,496.63% -99.27% -95.39% -1,013.44% -110.57% -33.84% 943.45% -91.89%
EPS Growth		 0.00% 575.00% 337.93% 1,900.00% -100.00% -90.91% -1,066.67% -114.29% -32.56% 1,000.00% -92.50%
Operating Cash Flow Growth		 -20.32% -1.23% 49.18% 288.75% -21.83% 63.10% 159.19% -126.54% 1,041.93% -43.47% 436.76%
Free Cash Flow Firm Growth		 97.94% 67.51% 264.09% 530.11% -76.11% -45.53% 107.67% 103.92% 128.83% 122.10% -550.13%
Invested Capital Growth		 -11.03% -10.35% -11.22% -12.50% -5.01% -6.89% -5.83% -3.83% -15.71% -8.31% 116.44%
Revenue Q/Q Growth		 -13.97% -0.87% 4.37% 17.18% 0.00% 6.78% 13.51% -11.84% -8.11% -5.65% 4.29%
EBITDA Q/Q Growth		 -69.75% -32.51% 41.48% 103.87% 0.00% -26.47% 584.61% -84.81% -40.07% 125.92% -29.79%
EBIT Q/Q Growth		 -122.10% -41.30% 70.87% 10,723.87% 0.00% -89.99% 160.98% -254.12% -64.53% 2,769.84% -90.25%
NOPAT Q/Q Growth		 -157.73% -64.45% 104.73% 1,162.15% 0.00% 91.01% -6.79% -226.54% -60.92% 2,435.29% -113.53%
Net Income Q/Q Growth		 -177.16% -60.18% 93.30% 15,961.29% 0.00% 107.35% -1,822.50% -104.90% -33.49% 1,356.89% -77.76%
EPS Q/Q Growth		 -177.78% -60.87% 91.67% 0.00% 0.00% 113.79% -1,350.00% -106.90% -34.09% 1,366.67% -78.57%
Operating Cash Flow Q/Q Growth		 -31.09% -17.03% 50.24% -7.23% 0.00% 25.32% 290.08% -138.42% 78.23% 99.15% -80.54%
Free Cash Flow Firm Q/Q Growth		 -21.41% -27.43% 5.59% 228.69% 0.00% 57.74% 82.74% -87.54% 51.65% 122.21% 6.61%
Invested Capital Q/Q Growth		 -5.14% -3.24% -1.07% -2.02% 0.00% -4.18% -2.49% 6.36% -6.30% -3.09% -0.43%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 89.48% 85.01% 89.99% 89.36% 88.65% 88.06% 87.26% 84.44% 84.74% 86.28% 85.41%
EBITDA Margin		 9.00% 25.58% 37.57% 27.72% 15.93% 14.24% 20.67% 3.43% 19.90% 34.74% 14.51%
Operating Margin		 -6.85% 12.29% 23.25% 13.41% -2.20% -0.61% 5.29% -12.97% 3.37% 20.52% -0.86%
EBIT Margin		 -3.89% 15.15% 25.58% 15.63% 0.17% 0.60% 6.43% -11.96% 6.84% 21.95% 0.72%
Profit (Net Income) Margin		 -7.89% 8.80% 21.91% 11.83% 0.09% 0.72% -10.38% -0.61% 11.02% 15.23% 0.99%
Tax Burden Percent		 202.83% 58.10% 85.66% 75.72% 51.03% 118.69% -161.55% 4.85% 187.96% 72.51% -393.92%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 105.61% 85.70% 95.66% -34.69%
Effective Tax Rate		 0.00% 41.90% 14.34% 24.28% 48.97% -18.69% 261.55% 0.00% -87.96% 27.49% 0.00%
Return on Invested Capital (ROIC)		 -5.05% 7.10% 0.00% 0.00% 0.00% -0.60% -6.91% -7.51% 5.48% 12.60% -0.70%
ROIC Less NNEP Spread (ROIC-NNEP)		 -3.70% 6.17% 0.00% 0.00% 0.00% -1.94% -4.68% -17.56% -1.89% 11.66% -1.77%
Return on Net Nonoperating Assets (RNNOA)		 1.31% -1.97% 0.00% 0.00% 0.00% 0.38% 0.67% 2.28% 0.21% -0.86% 0.56%
Return on Equity (ROE)		 -3.74% 5.12% 0.00% 0.00% 0.00% -0.22% -6.23% -5.23% 5.69% 11.73% -0.14%
Cash Return on Invested Capital (CROIC)		 19.61% 20.17% 11.89% 13.33% 5.14% 6.79% 8.76% 8.24% 23.09% 14.52% -69.31%
Operating Return on Assets (OROA)		 -1.96% 7.58% 0.00% 0.00% 0.00% 0.25% 2.63% -5.08% 2.67% 8.64% 0.29%
Return on Assets (ROA)		 -3.98% 4.40% 0.00% 0.00% 0.00% 0.29% -4.26% -0.26% 4.29% 5.99% 0.40%
Return on Common Equity (ROCE)		 -3.74% 5.12% 0.00% 0.00% 0.00% -0.22% -6.23% -5.23% 5.69% 11.73% -0.14%
Return on Equity Simple (ROE_SIMPLE)		 6.01% 0.00% 0.00% 0.00% 0.00% 0.00% 2.81% 4.71% 5.71% 0.00% 4.42%
Net Operating Profit after Tax (NOPAT)		 -7.18 12 35 17 -1.61 -1.18 -13 -12 9.73 25 -1.07
NOPAT Margin		 -4.79% 7.14% 19.91% 10.15% -1.12% -0.72% -8.54% -9.08% 6.33% 14.88% -0.60%
Net Nonoperating Expense Percent (NNEP)		 -1.34% 0.92% 1.31% 1.21% 0.75% 1.34% -2.23% 10.05% 7.37% 0.93% 1.07%
Return On Investment Capital (ROIC_SIMPLE)		 -0.68% 1.15% - - - -0.12% - - - 1.90% -
Cost of Revenue to Revenue		 10.52% 14.99% 10.01% 10.64% 11.35% 11.94% 12.74% 15.56% 15.26% 13.72% 14.59%
SG&A Expenses to Revenue		 60.03% 45.60% 39.70% 51.03% 60.23% 49.47% 53.74% 64.02% 55.67% 44.21% 63.33%
R&D to Revenue		 17.97% 16.45% 16.53% 15.56% 17.36% 14.21% 14.72% 17.98% 13.80% 10.62% 11.03%
Operating Expenses to Revenue		 96.32% 72.72% 66.74% 75.95% 90.84% 88.66% 81.97% 97.42% 81.38% 65.76% 86.27%
Earnings before Interest and Taxes (EBIT)		 -5.83 26 45 26 0.24 0.99 9.89 -16 11 37 1.28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 13 45 66 47 23 23 32 4.65 31 58 26
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.77 1.93 1.71 1.54 2.01 1.72 1.65 1.78 2.16 2.18 2.12
Price to Tangible Book Value (P/TBV)		 4.44 5.03 4.91 5.24 8.02 7.73 9.77 11.66 17.49 28.90 143.10
Price to Revenue (P/Rev)		 2.74 3.02 0.00 0.00 0.00 2.60 2.47 2.58 2.95 2.89 2.75
Price to Earnings (P/E)		 29.52 27.03 0.00 0.00 0.00 1,201.42 58.75 37.78 37.85 31.76 48.07
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.39% 3.70% 0.00% 0.00% 0.00% 0.08% 1.70% 2.65% 2.64% 3.15% 2.08%
Enterprise Value to Invested Capital (EV/IC)		 2.34 2.53 2.09 1.78 2.39 1.94 1.81 1.96 2.50 2.38 2.23
Enterprise Value to Revenue (EV/Rev)		 2.09 2.40 0.00 0.00 0.00 2.24 2.17 2.32 2.64 2.69 2.63
Enterprise Value to EBITDA (EV/EBITDA)		 8.17 8.83 0.00 0.00 0.00 15.05 11.22 13.11 12.25 11.32 16.76
Enterprise Value to EBIT (EV/EBIT)		 15.19 16.25 0.00 0.00 0.00 262.66 39.16 58.19 32.32 26.49 111.00
Enterprise Value to NOPAT (EV/NOPAT)		 27.73 25.80 0.00 0.00 0.00 0.00 63.55 44.17 37.82 38.96 71.25
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.49 9.25 0.00 0.00 0.00 12.26 14.15 20.50 10.92 15.37 12.58
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.22 11.85 16.56 12.46 45.38 27.53 20.02 23.25 9.90 15.70 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.05 0.05 0.05 0.06 0.06 0.05 0.02 0.53 0.48 0.53
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.35 -0.32 -0.28 -0.25 -0.25 -0.19 -0.14 -0.13 -0.11 -0.07 -0.32
Leverage Ratio		 1.35 1.35 1.37 1.39 1.68 1.65 1.69 1.70 1.97 1.99 1.95
Compound Leverage Factor		 1.35 1.35 1.37 1.39 1.68 1.65 1.69 1.79 1.69 1.91 -0.68
Debt to Total Capital		 2.83% 4.37% 4.42% 4.71% 5.24% 5.35% 4.79% 2.20% 34.52% 32.31% 34.49%
Short-Term Debt to Total Capital		 2.83% 4.37% 4.42% 4.71% 5.24% 5.35% 4.79% 2.20% 34.52% 32.31% 34.49%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.17% 95.63% 95.58% 95.29% 94.76% 94.65% 95.21% 97.80% 65.48% 67.69% 65.51%
Debt to EBITDA		 0.18 0.26 0.00 0.00 0.00 0.58 0.39 0.18 3.34 2.67 4.34
Net Debt to EBITDA		 -2.54 -2.26 0.00 0.00 0.00 -2.43 -1.52 -1.50 -1.43 -0.83 -0.72
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.60 0.77 0.00 0.00 0.00 -20.79 2.20 0.62 10.31 9.18 18.43
Net Debt to NOPAT		 -8.62 -6.59 0.00 0.00 0.00 87.62 -8.60 -5.06 -4.41 -2.87 -3.07
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.87 5.07 4.06 3.32 3.71 3.86 3.60 3.78 2.23 2.31 2.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.44 2.35 2.20 1.91 1.73 1.70 1.56 1.68 1.21 1.07 0.91
Quick Ratio		 2.16 2.04 1.88 1.62 1.42 1.38 1.19 1.14 0.51 0.91 0.77
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 67 85 117 111 34 51 32 18 141 93 -420
Operating Cash Flow to CapEx		 9,357.49% 20,847.89% 26,760.00% 55,662.50% 15,484.27% 0.00% 23,916.67% -11,870.44% 17,671.22% 0.00% 9,415.65%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.36 93.94 58.49 -243.43
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -20.74 32.64 17.29 8.03
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -20.92 32.46 17.30 7.94
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.50 0.50 0.00 0.00 0.00 0.41 0.41 0.42 0.39 0.39 0.41
Accounts Receivable Turnover		 4.55 4.62 0.00 0.00 0.00 3.92 3.99 4.30 4.63 4.24 4.43
Inventory Turnover		 1.24 1.18 0.00 0.00 0.00 0.99 1.05 1.06 1.03 0.98 1.13
Fixed Asset Turnover		 54.96 52.79 0.00 0.00 0.00 42.33 0.00 0.00 42.01 0.00 0.00
Accounts Payable Turnover		 0.95 1.00 0.00 0.00 0.00 0.95 0.92 0.86 1.00 0.82 0.89
Days Sales Outstanding (DSO)		 80.15 78.93 0.00 0.00 0.00 93.02 91.42 84.81 78.82 86.00 82.47
Days Inventory Outstanding (DIO)		 293.71 308.52 0.00 0.00 0.00 368.03 349.15 342.83 354.07 371.40 321.88
Days Payable Outstanding (DPO)		 385.22 365.26 0.00 0.00 0.00 383.20 395.51 422.22 363.58 447.82 410.07
Cash Conversion Cycle (CCC)		 -11.36 22.19 0.00 0.00 0.00 77.85 45.06 5.41 69.31 9.58 -5.72
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 597 629 651 658 671 702 733 751 707 754 778
Invested Capital Turnover		 1.05 0.99 0.00 0.00 0.00 0.83 0.81 0.83 0.87 0.85 1.16
Increase / (Decrease) in Invested Capital		 -74 -73 -82 -94 -35 -52 -45 -30 -132 -68 419
Enterprise Value (EV)		 1,394 1,590 1,362 1,171 1,606 1,362 1,326 1,469 1,764 1,796 1,736
Market Capitalization		 1,828 1,997 1,718 1,471 1,864 1,581 1,505 1,638 1,970 1,928 1,811
Book Value per Share		 $18.47 $18.76 $18.28 $17.42 $17.01 $16.87 $16.71 $16.89 $16.77 $16.39 $15.94
Tangible Book Value per Share		 $7.37 $7.19 $6.35 $5.11 $4.25 $3.75 $2.82 $2.58 $2.07 $1.23 $0.24
Total Capital		 1,061 1,083 1,054 1,005 981 974 958 941 1,393 1,309 1,302
Total Debt		 30 47 47 47 51 52 46 21 481 423 449
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -434 -406 -357 -300 -258 -219 -179 -168 -206 -132 -75
Capital Expenditures (CapEx)		 0.33 0.21 0.20 0.06 0.25 -0.04 0.15 0.16 0.28 -0.01 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -13 -8.13 -18 -17 0.11 7.52 40 0.33 7.95 -4.86
Debt-free Net Working Capital (DFNWC)		 436 441 395 330 281 255 208 192 633 469 387
Net Working Capital (NWC)		 406 394 348 282 230 203 162 171 152 46 -62
Net Nonoperating Expense (NNE)		 4.65 -2.89 -3.51 -2.83 -1.73 -2.36 2.83 -11 -7.22 -0.58 -2.82
Net Nonoperating Obligations (NNO)		 -434 -406 -357 -300 -258 -219 -179 -168 -206 -132 -75
Total Depreciation and Amortization (D&A)		 19 18 21 20 23 22 22 21 20 21 24
Debt-free, Cash-free Net Working Capital to Revenue		 -4.16% -1.90% 0.00% 0.00% 0.00% 0.02% 1.23% 6.31% 0.05% 1.19% -0.74%
Debt-free Net Working Capital to Revenue		 65.24% 66.64% 0.00% 0.00% 0.00% 41.97% 34.02% 30.23% 94.64% 70.33% 58.72%
Net Working Capital to Revenue		 60.75% 59.48% 0.00% 0.00% 0.00% 33.40% 26.51% 26.96% 22.71% 6.92% -9.42%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.21) $0.28 $0.70 $0.36 $0.00 $0.02 ($0.29) ($0.02) $0.31 $0.47 $0.03
Adjusted Weighted Average Basic Shares Outstanding		 55.86M 55.10M 55.15M 54.98M 54.80M 54.54M 54.61M 54.50M 54.38M 53.67M 53.79M
Adjusted Diluted Earnings per Share		 ($0.21) $0.27 $0.69 $0.36 $0.00 $0.04 ($0.29) ($0.02) $0.29 $0.44 $0.03
Adjusted Weighted Average Diluted Shares Outstanding		 55.86M 55.96M 56.02M 55.72M 55.63M 55.51M 54.61M 54.50M 62.45M 61.68M 55.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 55.99M 55.81M 55.22M 55.11M 54.97M 0.00 54.63M 54.59M 54.48M 54.38M 54.06M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.82 13 34 14 -2.17 -0.84 5.38 -12 2.47 23 -0.73
Normalized NOPAT Margin		 -1.21% 7.26% 19.42% 8.19% -1.51% -0.51% 3.49% -8.67% 1.61% 13.84% -0.41%
Pre Tax Income Margin		 -3.89% 15.15% 25.58% 15.63% 0.17% 0.60% 6.43% -12.63% 5.86% 21.00% -0.25%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -17.82 6.99 23.05 0.74
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.53 6.46 15.62 -0.62
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -18.00 6.81 23.05 0.66
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.70 6.28 15.63 -0.70
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Supernus Pharmaceuticals' Financials

When does Supernus Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Supernus Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Supernus Pharmaceuticals' net income changed over the last 10 years?

Supernus Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $73.87 million in 2024, falling from -$10.93 million in 2014. The previous period was $1.32 million in 2023. See Supernus Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Supernus Pharmaceuticals's operating income?
Supernus Pharmaceuticals's total operating income in 2024 was $81.67 million, based on the following breakdown:
  • Total Gross Profit: $583.91 million
  • Total Operating Expenses: $502.25 million
How has Supernus Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Supernus Pharmaceuticals' total revenue changed from $92.68 million in 2014 to $661.82 million in 2024, a change of 614.1%.

How much debt does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals' total liabilities were at $332.34 million at the end of 2024, a 6.7% decrease from 2023, and a 245.9% increase since 2014.

How much cash does Supernus Pharmaceuticals have?

In the past 10 years, Supernus Pharmaceuticals' cash and equivalents has ranged from $33.50 million in 2015 to $288.64 million in 2020, and is currently $69.33 million as of their latest financial filing in 2024.

How has Supernus Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Supernus Pharmaceuticals' book value per share changed from 0.95 in 2014 to 18.76 in 2024, a change of 1,878.6%.


Related Companies

This page (NASDAQ:SUPN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored